Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront
Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.
-------- Â
12:26
--------
12:26
Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals
Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
-------- Â
30:23
--------
30:23
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies
Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
-------- Â
21:11
--------
21:11
Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches
Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
-------- Â
30:39
--------
30:39
Seenu M. Hariprasad, MD - A Closer Look at Emerging Anti-VEGF Therapies in Retinal Vein Occlusion Management: Practical Guidance for Specialists
Please visit answersincme.com/UPU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing patients with retinal vein occlusion (RVO) discusses the use of longer-acting anti-VEGF treatments for treating RVO. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with retinal vein occlusion (RVO); Differentiate the clinical profiles of available and emerging anti-VEGF treatments for macular edema following RVO, based on the latest evidence; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
South Africa